Signatera for melanoma – pro
There are no supportive studies or guideline recommendations. Trials are being designed. Brunsgaard et al wrote: ” ..successful design of a personalized, tumor-informed mPCR NGS-based ctDNA assay is feasible for patients with melanoma, particularly in resectable stage III disease. Research tissue requirements may have impaired evaluation of the Stage IIB patient population, and conclusions regarding use in this subgroup of patients must be taken with caution. This evidence supports further investigation into the use of the platform to assess the clinical utility of ctDNA in high-risk melanoma patients. Larger scale prospective studies are warranted to evaluate the use of serial ctDNA monitoring for early detection of recurrence, and its potential impact on surveillance imaging protocols and adjuvant therapy decisions in high-risk melanoma.”
Brunsgaard EK, Bowles TL, Asare EA, Grossmann K, Boucher KM, Grossmann A, Jackson JA, Wada DA, Rathore R, Budde G, Grandemange A, Hyngstrom JR. Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma. Melanoma Res. 2023 Jun 1;33(3):184-191. doi: 10.1097/CMR.0000000000000892. Epub 2023 Apr 5. PMID: 37040662; PMCID: PMC10144272.
Zeynep Eroglu et al, Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Cancer Volume129, Issue11 1 June 2023 Pages 1723-1734
NCCN Melanoma 2025